Cargando…

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy

BACKGROUND: Intrathecal administration of nusinersen in adult spinal muscular atrophy (SMA) patients presents challenges owing to severe scoliosis and previous spinal surgery with metal implantation. In patients with a complex spinal situation, the potential risks of the intrathecal administration m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cordts, Isabell, Lingor, Paul, Friedrich, Benjamin, Pernpeintner, Verena, Zimmer, Claus, Deschauer, Marcus, Maegerlein, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Therapeutic Perspectives in Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974755/ https://www.ncbi.nlm.nih.gov/pubmed/32010224 http://dx.doi.org/10.1177/1756286419887616

Ejemplares similares

Radiation dose reduction for CT-guided intrathecal nusinersen administration in adult patients with spinal muscular atrophy
por: Cordts, Isabell, et al.
Publicado: (2020)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
por: Osmanovic, Alma, et al.
Publicado: (2021)

Symptomatic intracranial hypertension in an adult patient with spinal muscular atrophy and arachnoid cysts receiving nusinersen
por: Machetanz, Gerrit, et al.
Publicado: (2023)

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment
por: Freigang, Maren, et al.
Publicado: (2021)

Intrathecal administration of nusinersen for spinal muscular atrophy: report of three cases with severe spinal deformity
por: Nakao, Sayo, et al.
Publicado: (2020)

Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy
por: Kizina, Kathrin, et al.
Publicado: (2019)

Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy
por: Günther, René, et al.
Publicado: (2019)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
por: Haché, Manon, et al.
Publicado: (2016)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018)

Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy
por: Orbach, Rotem, et al.
Publicado: (2022)

Scoliosis Orthopedic Surgery Combined With Nusinersen Intrathecal Injection Significantly Improved the Outcome of Spinal Muscular Atrophy Patient: A Case Report
por: Xu, Beiyu, et al.
Publicado: (2022)

Intrathecal Administration of Nusinersen Using the Ommaya Reservoir in an Adult with 5q-Related Spinal Muscular Atrophy Type 1 and Severe Spinal Deformity
por: Papaliagkas, Vasileios, et al.
Publicado: (2021)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen
por: Yae, Yukako, et al.
Publicado: (2022)

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)

Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020)

Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study
por: Vázquez‐Costa, Juan F., et al.
Publicado: (2022)

Assessment of Health-Related Quality of Life in Adult Spinal Muscular Atrophy Under Nusinersen Treatment—A Pilot Study
por: Thimm, Andreas, et al.
Publicado: (2022)

Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
por: Kizina, K., et al.
Publicado: (2020)

Parents’ perspectives on nusinersen treatment for children with spinal muscular atrophy
por: van Kruijsbergen, Mette, et al.
Publicado: (2021)

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study
por: Acsadi, Gyula, et al.
Publicado: (2021)

Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era
por: Al Amrani, Fatima, et al.
Publicado: (2022)

Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
por: Nuzzo, Tommaso, et al.
Publicado: (2023)

Circulating microRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy
por: Chen, Tai-Heng
Publicado: (2020)

Nusinersen in type 0 spinal muscular atrophy: should we treat?
por: Tiberi, Eloisa, et al.
Publicado: (2020)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
por: Qiu, Jiaying, et al.
Publicado: (2022)

Ultra-low radiation dose protocol for CT-guided intrathecal nusinersen injections for patients with spinal muscular atrophy and severe scoliosis
por: Rosiak, Grzegorz, et al.
Publicado: (2021)

Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy
por: Binz, Camilla, et al.
Publicado: (2022)

Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study
por: Wang, Zhen, et al.
Publicado: (2023)

Ultrasound-guided interlaminar approach for nusinersen administration in patients with spinal muscular atrophy with spinal fusion or severe scoliosis
por: Wei, Cuijie, et al.
Publicado: (2023)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
por: Thokala, Praveen, et al.
Publicado: (2020)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
por: Osmanovic, Alma, et al.
Publicado: (2021)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1sp29h6crhvo3i9bjepr76buen